carotid artery disease. The Company plans to issue a press release at
-- Analyst Meeting. At 5:30 p.m., the Company will host an analyst
meeting in the Grand Ballroom of the Renaissance Hotel. The meeting is
open to the media and will include a DES clinical program update by Dr.
Donald Baim and a DES business update by Paul LaViolette. This meeting
is being webcast and can be accessed in the Investor Relations section
of Boston Scientific's website, http://www.bostonscientific.com. Please visit
the website for details on how to register for the webcast or to access
a replay, which will be archived for 90 days.
-- Symposium on Drug-Eluting Stents. From 8:00 - 10:00 p.m., the Company
will host a symposium entitled "Preclinical to Patients: The DES
Pathway" chaired by Keith D. Dawkins, M.D., in the Grand Ballroom of
the Renaissance Hotel. The symposium will include presentations on
drug development and actions of current DES molecules by Aloke V. Finn,
M.D.; the state of the DES market by Dr. Dawkins; late-breaking data on
next-generation DES by Dr. Turco; and impact of dual anti-platelet
therapy on DES outcomes by Steven R. Steinhubl, M.D. A reception will
be held prior to the symposium at 7:00 p.m.
The Company will also release additional safety and efficacy data from its comprehensive DES clinical trial program, which will be presented at TCT as e- posters. Details can be found on the official TCT program.
Boston Scientific will present its latest innovations and live case
broadcasts at booth 3021 in the Exhibition Hall. Key product demonstrations
will include drug-eluting stents, carotid artery stenting and peripheral
interventions. In addition, Boston Scientific will i
|SOURCE Boston Scientific Corporation|
Copyright©2007 PR Newswire.
All rights reserved